Ted Lau
Genentech
8 Papers
27 Citations
Ted Lau is an academic researcher from Genentech. The author has contributed to research in topics: Wnt signaling pathway & Axin Protein. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells
Maia Vinogradova,Victor S. Gehling,Amy Gustafson,Shilpi Arora,Charles Tindell,Catherine Wilson,Kaylyn E. Williamson,Gulfem D. Guler,Pranoti Gangurde,Wanda Manieri,Jennifer Busby,E. Megan Flynn,Fei Lan,Hyojin Kim,Shobu Odate,Andrea G. Cochran,Yichin Liu,Matthew Wongchenko,Yibin Yang,Tommy K. Cheung,Tobias M. Maile,Ted Lau,Michael R. Costa,Ganapati V. Hegde,Erica L. Jackson,Robert M. Pitti,David Arnott,Christopher M. Bailey,Steve Bellon,Richard T. Cummings,Brian K. Albrecht,Jean-Christophe Harmange,James R. Kiefer,Patrick Trojer,Marie Classon +34 more
TL;DR: Findings show that pretreatment of cancer cells with a KDM5-specific inhibitor results in the ablation of a subpopulation of cancers cells that can serve as the founders for therapeutic relapse.
299
Ubiquitin Ligase RNF146 Regulates Tankyrase and Axin to Promote Wnt Signaling
Marinella Callow,Hoanh Tran,Lilian Phu,Ted Lau,James Lee,Wendy Sandoval,Peter Liu,Sheila Bheddah,Janet Tao,Jennie R. Lill,Jo-Anne Hongo,David M Davis,Donald S. Kirkpatrick,Paul Polakis,Mike Costa +14 more
TL;DR: RNF146, tankyrase, and Axin form a protein complex, and it is demonstrated that RNF146 mediates ubiquitylation of all three proteins to target them for proteasomal degradation.
Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1.
Yu Zhong,Paula Katavolos,Trung Nguyen,Ted Lau,Jason Boggs,Amy Sambrone,David Kan,Mark Merchant,Eric Harstad,Dolores Diaz,Mike Costa,Melissa Schutten +11 more
TL;DR: The clinical utility of tankyrase inhibitors is likely limited by the on-target intestinal toxicity and a therapeutic index < 1 in mice.
88
Patent
Methods of treating cancer and preventing cancer drug resistance
Shilpi Arora,Michael R. Costa,Ted Lau,Patrick Trojer,Brian K. Albrecht,Shane Buker,Marie Classon,Victor S. Gehling,Jean-Christophe Harmange,Erica L. Jackson,Jun Liang,Heidi S. Phillips,Peter Sandy,Jeffrey Settleman,Jean-Philippe Stephan +14 more
- 14 Mar 2014
TL;DR: In this article, methods of treating and/or preventing cancer drug resistance using antagonists of KDM5 were presented, which can be used to prevent cancer drug-resistant drugs from being introduced.
27
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Steffan Vartanian,James Lee,Christiaan Klijn,Florian Gnad,Maria Bagniewska,Gabriele Schaefer,Donglu Zhang,Jenille Tan,Sara A. Watson,Liling Liu,Honglin Chen,Yuxin Liang,Colin K. Watanabe,Trinna L. Cuellar,David Kan,Ryan J. Hartmaier,Ted Lau,Michael R. Costa,Scott E. Martin,Mark Merchant,Benjamin Haley,David Stokoe +21 more
TL;DR: Alternative pathways critical for Nrf2-dependent growth in KEAP1-mutant cell lines are identified, including the redox proteins thioredoxin and peroxiredoxin, as well as growth factor receptors IGF1R and ERBB3, and IGF 1R inhibition was effective in KE AP1 mutant cells compared to WT, especially under conditions of anchorage-independent growth.